ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Prana Biotechnology Raises Approximately 6 Million US Dollars To Fully Fund Its Phase IIa Clinical Trial Of PBT2 In Patients With Alzheimer's Disease
Prana
Biotechnology Limited (Nasdaq: PRAN; ASX: PBT), today announced it has
entered into agreements to raise approximately 6.0 million US Dollars (7.8
million A Dollars) from new institutional investors in Australia, existing
institutional investors in the United States and a founding member of the
Company. As a result, the Company now has 10.2 million US Dollars (13.3 million A Dollars)
in cash to immediately commence its Phase IIa trial of PBT2 in Patients
with early Alzheimer's disease, for which it has received full regulatory
approval in Sweden.
The investment involves the purchase of 21.8 million ordinary shares
(equivalent to 2.18 million ADRs) at a price of A$0.357 per ordinary share
(approximately US$2.74 per ADR). In addition, the investors receive three-
year options to purchase an additional 4.35 million ordinary shares
(equivalent to 435,000 ADRs) at an exercise price of A$0.446 per ordinary
share (approximately US$3.42 per ADR), which could raise an additional
US$1.5 million (A$1.9 million) for the Company.
"We believe these commitments from new and existing investors reinforce
the enthusiasm for PBT2 and its potential as an effective treatment for
Alzheimer's disease," said Geoffrey Kempler, chairman and CEO. "The
proceeds raised in this private offering will fully fund the upcoming Phase
IIa clinical trial of PBT2 to its conclusion. We are optimistic that this
trial will demonstrate the safety and tolerability, as well as the potency
and efficacy of PBT2 for the treatment of Alzheimer's disease. We believe
that our drug, unlike any currently available Alzheimer's drug, could offer
a disease modifying therapy for patients, which is of enormous interest to
major pharmaceutical companies."
Prana has received the regulatory and ethics approvals needed to start
the Phase IIa study of patients with early Alzheimer's disease at seven
Swedish sites. Screening of patients will commence next week. The Company
plans to announce the results of the PBT2 Phase IIa trial in the fourth
quarter of calendar 2007.
Mr. Kempler concluded, "PBT2 is one of over 300 proprietary molecules
that Prana has developed as candidates to treat a variety of
neurodegenerative disorders. We plan to use the balance of the funds raised
today for other activities over the next 12 months, designed to strengthen
the evidence in support of our MPAC ("Metal Protein Attenuating Compound")
theory and development platform for our target diseases."
The private placement will proceed in two stages: (1) shares available
for immediate issue, which represents a total of approximately A$5.6
million; and (2) the balance to be issued upon the Company receiving
shareholder approval at an Extraordinary General Meeting, which is expected
to occur on or about December 28, 2006.
Prana Biotechnology had 12.85 million ADRs (128,474,260 ordinary
shares) outstanding as of October 13, 2006; this private placement will
increase the total issued shares to 15.02 million ADRs (150,238,728
ordinary shares). Each 10 Prana ordinary shares traded on the ASX (ticker:
PBT) is equivalent to a single ADR traded on the NASDAQ Stock Market
(ticker: PRAN).
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into
Alzheimer's disease and other major age-related neuro-degenerative
disorders. The company was incorporated in 1997 and listed on the
Australian Stock Exchange in March 2000 and listed on NASDAQ in September
2002. Researchers at prominent international institutions including the
University of Melbourne and Massachusetts General Hospital, a teaching
hospital of Harvard Medical School, discovered Prana's technology.
For further information, please visit our web site at http://www.pranabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such
forward-looking statements by use of such words as "expects," "intends,"
"hopes," "anticipates," "believes," "could," "may," "evidences" and
"estimates," and other similar expressions, but these words are not the
exclusive means of identifying such statements. Such statements include,
but are not limited to any statements relating to the Company's drug
development program, including, but not limited to the initiation, progress
and outcomes of clinical trials of the Company's drug development program,
including, but not limited to, PBT2, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties relating to
the difficulties or delays in financing, development, testing, regulatory
approval, production and marketing of the Company's drug components,
including, but not limited to, PBT2, the ability of the Company to procure
additional future sources of financing, unexpected adverse side effects or
inadequate therapeutic efficacy of the Company's drug compounds, including,
but not limited to, PBT2, that could slow or prevent products coming to
market, the uncertainty of patent protection for the Company's intellectual
property or trade secrets, including, but not limited to, the intellectual
property relating to PBT2, and other risks detailed from time to time in
the filings the Company makes with Securities and Exchange Commission
including its annual reports on From 20-F and its reports on Form 6-K. Such
statements are based on management's current expectations, but actual
results may differ materially due to various factions including those risks
and uncertainties mentioned or referred to in this press release.
Accordingly, you should not rely on those forward-looking statements as a
prediction of actual future results.
Prana Biotechnology Limited
http://www.pranabio.com
Prana Biotehnologie ridicã la aproximativ 6 milioane de dolari SUA pentru a fondului sãu deplin IIa studiu clinic de fazã de PBT2 la pacienþii cu Boala Alzheimer - Prana Biotechnology Raises Approximately 6 Million US Dollars To Fully Fund Its Phase IIa Clinical Trial Of PBT2 In Patients With Alzheimer's Disease - articole medicale engleza - startsanatate